drugset / Trial / NCT04627922

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

NCT04627922

RandomizedParallel-groupDouble-blindTreatment

Summary

Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.

Timeline

Start
2021-08-25
Primary completion
2025-06-30
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 3600 mg